FCX CLASS ACTION: BFA Law Alerts Freeport-McMoRan Inc. Investors of the Pending Securities Fraud Class Action and Upcoming January 12 DeadlineNovember 18, 2025 3:33 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 18, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company's senior executives for securities fraud after significant ...

Core Viewpoint - A class action securities lawsuit has been filed against RCI Hospitality Holdings, Inc. to recover losses incurred by shareholders due to alleged securities fraud between December 15, 2021, and September 16, 2025 [2][3]. Group 1: Lawsuit Details - The complaint alleges that the defendants engaged in tax fraud and bribery to conceal this fraud, resulting in an understatement of the legal risks facing the company [3]. - It is claimed that the defendants' statements regarding the company's business, operations, and prospects were materially false and misleading, lacking a reasonable basis at all relevant times [3]. Group 2: Next Steps for Shareholders - Shareholders who suffered losses during the specified timeframe, even if they still hold their shares, are encouraged to learn about their rights to seek recovery [4]. Group 3: Legal Firm Background - Levi & Korsinsky LLP has a strong reputation in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

New York, New York--(Newsfile Corp. - November 14, 2025) - If you suffered a loss on your Marex Group plc (NASDAQ: MRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/marex-group-plc-lawsuit-submission-form?prid=177499&wire=5&utm_campaign=1or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.THE LAWSUI ...

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud related to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Cytokinetics investors affected by alleged securities fraud between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made materially false statements regarding the NDA submission timeline and FDA approval expectations, claiming approval in the second half of 2025 based on a September 26, 2025, PDUFA date [2]. - The company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [2]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA about safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Cytokinetics during the relevant timeframe have until November 17, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against KBR, Inc. alleging securities fraud that affected investors between May 6, 2025, and June 19, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global household goods contract [2] - It is alleged that the defendants' statements about KBR's business operations and prospects were materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 18, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Marex Group plc ("Marex Group plc" or the "Company") (NASDAQ: MRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Marex Group plc investors who were adversely affected by alleged securities fraud between May 16, 2024 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/marex-group-plc-l ...

Core Viewpoint - MoonLake Immunotherapeutics has been sued for securities fraud, with allegations that the company misrepresented its clinical data and the efficacy of its investigational drug sonelokimab [1][3][4]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its Phase 3 VELA trials for sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a superior clinical response for patients compared to competitors [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit over competitors, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the VELA Phase 3 trials, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [7].

Core Viewpoint - A securities fraud class action against Maison Solutions Inc. has survived a motion to dismiss, and the case is currently stayed as parties attempt to reach a settlement [3][4]. Group 1: Allegations and Legal Proceedings - The class action complaint alleges that Maison Solutions made materially false and misleading statements in its Registration Statement and throughout the Class Period (October 5, 2023 to December 15, 2023) [3]. - Key allegations include the failure to disclose that vendor XHJC Holdings Inc. is a related party, and that the CEO and related entities allegedly used supermarkets to defraud the EB-5 visa program [3]. - As a result of these allegations, the positive statements made by the defendants regarding the company's business and prospects were deemed materially misleading [3]. Group 2: Shareholder Actions - Current shareholders who purchased shares on or shortly after the October 5, 2023 IPO may seek corporate reforms, the return of funds to the company, and a court-approved incentive award at no cost [2][5]. - Shareholders are encouraged to contact Grabar Law Office for further information and assistance regarding their claims [2][5].

Core Viewpoint - Kaskela Law LLC is investigating Priority Technology Holdings, Inc. due to a significant decline in its stock value, which has dropped over 50% since February 2025 [1][2]. Group 1: Stock Performance - Priority's common stock has decreased from over $12.00 per share to less than $6.00 per share, representing a cumulative decline of over 50% in value [1]. Group 2: Legal Investigation - The investigation aims to determine if Priority and its officers and directors violated securities laws or breached fiduciary duties related to recent corporate actions [2]. - Shareholders of Priority are encouraged to contact Kaskela Law LLC for more information regarding their legal rights and options [2].

Core Viewpoint - A class action securities lawsuit has been filed against RCI Hospitality Holdings, Inc. alleging securities fraud affecting investors between December 15, 2021, and September 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants engaged in tax fraud and bribery to conceal this fraud, leading to an understatement of the legal risks faced by the company [3]. - It is alleged that the defendants' statements regarding the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 20, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].